JP2025500481A5 - - Google Patents

Info

Publication number
JP2025500481A5
JP2025500481A5 JP2024538257A JP2024538257A JP2025500481A5 JP 2025500481 A5 JP2025500481 A5 JP 2025500481A5 JP 2024538257 A JP2024538257 A JP 2024538257A JP 2024538257 A JP2024538257 A JP 2024538257A JP 2025500481 A5 JP2025500481 A5 JP 2025500481A5
Authority
JP
Japan
Prior art keywords
saponin
composition
nucleic acid
use according
core structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500481A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2022/050735 external-priority patent/WO2023121445A1/en
Publication of JP2025500481A publication Critical patent/JP2025500481A/ja
Publication of JP2025500481A5 publication Critical patent/JP2025500481A5/ja
Pending legal-status Critical Current

Links

JP2024538257A 2021-12-22 2022-12-20 筋消耗性障害を治療するための治療用核酸とサポニンとを含む組成物 Pending JP2025500481A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2030217 2021-12-22
NL2030217 2021-12-22
PCT/NL2022/050735 WO2023121445A1 (en) 2021-12-22 2022-12-20 Compositions comprising therapeutic nucleic acid and saponin for the treatment of muscle-wasting disorders

Publications (2)

Publication Number Publication Date
JP2025500481A JP2025500481A (ja) 2025-01-09
JP2025500481A5 true JP2025500481A5 (cg-RX-API-DMAC7.html) 2025-12-23

Family

ID=81585487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538257A Pending JP2025500481A (ja) 2021-12-22 2022-12-20 筋消耗性障害を治療するための治療用核酸とサポニンとを含む組成物

Country Status (4)

Country Link
US (1) US20250250564A2 (cg-RX-API-DMAC7.html)
EP (1) EP4452281A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500481A (cg-RX-API-DMAC7.html)
WO (1) WO2023121445A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
WO2020219820A1 (en) 2019-04-25 2020-10-29 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
JP2026519131A (ja) * 2023-06-02 2026-06-11 サプリーム テクノロジーズ,ベー.フェー. 細胞内分子標的を介して作用する治療エフェクター成分のための改善された治療レジメン
WO2026087695A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for metabolic disorder
WO2026087680A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for cardiovascular disease
WO2026087678A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for renal disorders
WO2026119464A1 (en) 2024-12-03 2026-06-11 Sapreme Technologies B.V. Treatment for cns-related disease
CN121270643B (zh) * 2025-12-09 2026-03-17 成都健腾生物技术有限公司 一种麦仙翁皂苷e的生产制备工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
CA2522213A1 (en) * 2003-04-08 2004-10-28 Dante J. Marciani Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
WO2018080658A1 (en) 2016-10-27 2018-05-03 Aalborg University Therapeutic targeting of a microrna to treat duchenne muscular dystrophy
KR20240172236A (ko) 2017-01-06 2024-12-09 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
AU2019315593B2 (en) 2018-08-02 2026-05-21 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
US20220023433A1 (en) 2018-12-21 2022-01-27 Sapreme Technologies B.V. Saponin Conjugates
JP7858532B2 (ja) 2020-01-10 2026-05-14 ダイン セラピューティクス,インコーポレーテッド 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用

Similar Documents

Publication Publication Date Title
JP2025501610A5 (cg-RX-API-DMAC7.html)
JP2025500482A5 (cg-RX-API-DMAC7.html)
ES3052234T3 (en) Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
US8389491B2 (en) Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
CN118434449A (zh) 包含用于治疗肌肉消耗障碍的治疗性核酸和靶向皂苷的组合物
JP7197463B2 (ja) Smn2の調節のための化合物及び方法
JP2025500481A (ja) 筋消耗性障害を治療するための治療用核酸とサポニンとを含む組成物
EP4592390A1 (en) Specifically modified rnai reagent and composition
JP2024505151A5 (cg-RX-API-DMAC7.html)
CN111971051A (zh) 用增加tm的核苷酸修饰的双链核酸抑制剂分子
EP4671372A2 (en) Translation-enhancing nucleic acid compounds: Upward regulation 1 coupled with ASO (ACT-UP1) and their uses
US20230107967A1 (en) Compositions and methods for inhibiting alpha-1 antitrypsin expression
WO2022092279A1 (ja) siRNA及び医薬組成物並びに予防及び/又は治療剤
US20240150768A1 (en) Methods for the treatment of nash with advanced fibrosis and/or cirrhosis
TW202430192A (zh) 用於治療nash之劑量方案
JP7560544B2 (ja) 遺伝子スプライシングを調節するために有用な化合物および方法
CN121816200A (zh) 经由细胞内分子靶标起作用的治疗性效应子组分的改善的治疗方案
CN121759452A (zh) 用于抑制MARC1基因表达的siRNA及其缀合物和用途
HK40118872B (en) Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
HK40118872A (en) Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
HK40129943A (en) Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
CN117120041A (zh) 胞外囊泡组合物
HK40008058A (en) Compounds and methods for modulation of smn2
HK40008058B (en) Compounds and methods for modulation of smn2